What makes pharmaceutical stocks a good investment?

Pharmaceutical stocks can be attractive investments because they operate in an essential industry with consistent demand. The healthcare sector is expected to grow at about 7% annually, reaching $1.9 trillion by 2027. These companies typically invest heavily in research for new treatments, which can lead to breakthroughs and potentially significant returns. They also tend to be more stable during economic downturns since medical needs continue regardless of market conditions.

What is Market Cap and why does it matter for pharma stocks?

Market Cap (Market Capitalization) is the total value of a company's outstanding shares, calculated by multiplying the stock price by the number of shares. For pharma companies, a larger market cap often indicates a more established company with diverse product portfolios and greater resources for research. Smaller market cap companies might be more focused on specific treatments or technologies with higher growth potential but possibly more risk. This helps you understand the company's size and relative stability within the pharmaceutical industry.

What is an Analyst Rating and how should I use it?

An Analyst Rating is a professional opinion about a stock's potential performance based on the company's finances, product pipeline, and market conditions. For pharmaceutical companies, these ratings consider factors like upcoming drug approvals, patent expirations, and clinical trial results. Ratings typically range from "Buy" to "Hold" to "Sell." While helpful as one data point in your decision-making process, remember that analysts can sometimes be overly optimistic or miss important developments, so it's best to consider ratings alongside other factors.

How do pharmaceutical companies like Moderna and Novavax grow so quickly?

Companies like Moderna and Novavax can experience rapid growth through breakthrough innovations and timely solutions to health crises, as seen during the COVID-19 pandemic. When pharmaceutical companies develop successful new treatments or vaccines, especially for widespread conditions, they can see dramatic revenue increases. These companies typically reinvest in their research pipelines, which can lead to more breakthroughs and continued growth. However, this growth often comes with volatility, as success depends on clinical trials, regulatory approvals, and market adoption of their products.

23 handpicked stocks

Pharma

Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.

+13

Han Tan | Market Analyst

Published on May 6

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

Johnson & Johnson

JNJ

Current price

$242.04

Pfizer Inc.

PFE

Current price

$26.86

Moderna, Inc.

MRNA

Current price

$53.39

Novartis AG

NVS

Current price

$154.25

Merck & Co. Inc.

MRK

Current price

$115.91

Eli Lilly and Company

LLY

Current price

$977.25

Unlock all stocks by downloading the app for FREE.

It only takes 60 seconds.

Your Basket's Financial Footprint

Summary of market cap composition for the Pharma basket.

Key Takeaways for Investors:

Large-cap dominance suggests generally lower volatility and more stable returns, closely tracking broad market healthcare performance.
Suitable as a core, long-term holding for diversified portfolios rather than a speculative or high-conviction growth position.
Expect steady, incremental appreciation over time; less likely to deliver explosive short-term gains.

Total Market Cap

JNJ: $462.30B
PFE: $141.29B
MRNA: $10.74B
Other

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.

If you invested across these assets:

≈

In 12 months it might be worth:

$1,000.00

+10.91%

≈

About This Group of Stocks

Our Expert Thinking

Pharmaceutical companies offer a unique combination of stability and growth potential. With consistent demand for healthcare and ongoing innovation in treatments, this industry is projected to grow at 7% annually, reaching $1.9 trillion by 2027.

What You Need to Know

These pharma stocks represent companies focused on developing life-improving and life-saving medications. The healthcare sector tends to be more resilient during economic downturns, as medical needs remain constant regardless of market conditions.

Why These Stocks

This collection includes established pharmaceutical giants alongside innovative biotech companies. These stocks were selected based on their market leadership, research capabilities, and potential for growth through new treatments and medications.

Group Performance Snapshot

10.91%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 10.91% over the next year.

16 of 23

Stocks Rated Buy by Analysts

16 of 23 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

💊

Healthcare's Golden Opportunity

The pharma industry is expected to reach $1.9 trillion by 2027. Getting in now means you could benefit from this massive growth trajectory as companies develop new treatments.

🔬

Innovation Worth Watching

Companies like Moderna and Novavax showed how pharmaceutical breakthroughs can lead to extraordinary gains. These stocks represent the future of healthcare innovation.

📈

Recession-Resistant Potential

Healthcare needs remain constant regardless of economic conditions, making pharma stocks potentially more stable during market downturns while still offering growth.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

China App Ecosystem (App Store Fee Cuts Explained)

Following pressure from local regulators, Apple is reducing its App Store commission rates in China, providing immediate relief to software creators in the region. This theme focuses on the Chinese app developers, mobile gaming publishers, and tech giants poised to enjoy enhanced profit margins from these reduced operating costs.

eVTOL Flight Tests | Advanced Air Mobility Stocks

Joby Aviation's recent initiation of FAA-conforming flight tests marks a massive leap forward for the commercialization of electric air taxis. This regulatory breakthrough creates an exciting investment opportunity across the broader advanced air mobility sector, benefiting competing manufacturers and specialized infrastructure developers.

Workwear Mergers | Weighing Growth Against Saturation

Cintas's $5.5 billion acquisition of UniFirst highlights a massive consolidation wave in the uniform and facility services industry. Investors can capitalize on this trend by looking at other commercial service providers, safety equipment manufacturers, and B2B apparel suppliers positioned for growth or potential buyouts.

Pharma

Top Picks from This Group

Your Basket's Financial Footprint

12 Month Growth Potential

About This Group of Stocks

Our Expert Thinking

What You Need to Know

Why These Stocks